Analysts on Wall Street project that Veeva Systems (VEEV) will announce quarterly earnings of $1.53 per share in its forthcoming report, representing an increase of 26.5% year over year. Revenues are projected to reach $667.21 million, increasing 13% from the same quarter last year. The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this ...

Veeva Systems (VEEV) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. Over the past month, shares of this provider of cloud-based software services for the life sciences industry have returned +9.3%, compared to the Zacks S&P 500 composite's +2.2% change. During this period, the Zacks Internet - Software industry, which Veeva falls in, has gained 7.2%. The key ques ...

Life sciences organizations now manage all quality control data and processes in one solution for greater efficiency and speed PLEASANTON, Calif., Aug. 22, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced increasing momentum for Veeva Vault LIMS, a modern cloud solution that simplifies end-to-end quality control (QC) business processes. Vault LIMS is unified with Veeva Vault Quality, enabling customers to share data and content across quality applications for more informed batch release decis ...

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though? Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Veeva Systems (VEEV) . Veeva currently has an average brokerage ...

In the latest trading session, Veeva Systems (VEEV) closed at $194.28, marking a +0.92% move from the previous day. The stock fell short of the S&P 500, which registered a gain of 0.97% for the day. Meanwhile, the Dow experienced a rise of 0.58%, and the technology-dominated Nasdaq saw an increase of 1.39%. Heading into today, shares of the provider of cloud-based software services for the life sciences industry had gained 5.05% over the past month, outpacing the Computer and Technology sector's loss of 5.3 ...

Core Insights - The 2024 Veeva R&D and Quality Summit will feature industry leaders from major pharmaceutical companies to discuss advancements in drug development [1][2] - The event aims to enhance collaboration and innovation in the life sciences sector through connected systems across various functions [1][4] Group 1: Event Overview - The Veeva R&D and Quality Summit is one of the largest life sciences events, attracting over 2,000 executives and offering more than 100 sessions [2] - Veeva CEO Peter Gassner will deliver the opening keynote, focusing on how connected data and systems can streamline drug development and accelerate time to market [2] Group 2: Key Presentations - AbbVie and Merck will discuss the transformation of pharmacovigilance and its impact on operational visibility and efficiency [2][3] - Astellas will present its holistic approach to enhancing clinical processes for improved speed and transparency [3] - Eikon Therapeutics will highlight the importance of establishing a scalable foundation for efficient development from clinical trials to product launch [3] Group 3: Innovations in Quality Control - Neurogene and Verve Therapeutics will address modernizing quality control through simplified processes and digital-first execution [3] - Sanofi will showcase the use of AI-powered translation to expedite submission timelines [3] - UCB will share its journey in enterprise eCOA to standardize patient data capture and accelerate delivery [4] Group 4: Veeva's Commitment - Veeva Systems emphasizes its commitment to customer success by providing integrated software, data, and services to advance innovation in the life sciences [4] - The summit serves as a platform for sharing learnings, fresh ideas, and strategies to improve collaboration and accelerate the delivery of novel products [4]

PLEASANTON, Calif., Aug. 7, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) will announce financial results for its second quarter, which ended July 31, 2024, after market close on August 28, 2024. Veeva will host a conference call and webcast that day at 2:00 p.m. PT (5:00 p.m. ET) to discuss its financial results. Veeva will post prepared remarks to its investor relations website at https://ir.veeva.com approximately at 1:05 p.m. PT (4:05 p.m. ET). A webcast replay will be available on the website followi ...

Veeva Systems (VEEV) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Shares of this provider of cloud-based software services for the life sciences industry have returned +5.9% over the past month versus the Zacks S&P 500 composite's +1.1% change. The Zacks Internet - Software industry, to which Veeva belongs, has lost 6.4% over this period. Now the key question is: Where could ...

Core Insights - Veeva Systems' latest report indicates that targeted pre-launch scientific outreach significantly enhances the impact of medical affairs teams on treatment adoption, with biopharmas investing in these activities achieving 40% faster adoption rates compared to those that invest less [1][6]. Group 1: Pre-launch Scientific Outreach - Companies that engage key experts at congresses, develop clinical guidelines, and secure publication coverage before product launch experience a 40% faster treatment adoption [6]. - Investment in pre-launch congress activities has the strongest influence on treatment decisions post-approval, surpassing the impact of clinical guidelines and publications [6]. - Engaging early-career healthcare professionals (HCPs) is crucial, as they are four times more likely to initiate patients on new treatments and significantly more active in congress participation and digital engagement [6]. Group 2: Influence of Congresses and Early-career Experts - Congresses and the subsequent digital discussions are pivotal in increasing scientific awareness and facilitating impactful medical conversations [5][6]. - Early-career HCPs are five times more likely to speak at congresses, eleven times more likely to engage digitally, and seven times more likely to publish their findings [6]. - The analysis is based on over 600 million HCP interactions and activities from more than 80% of commercial biopharma field teams globally, making it a comprehensive industry benchmark [9].

Core Insights - Neuraxpharm will implement Veeva Vault QualityDocs and Veeva Vault Training to enhance its quality operations and compliance [1][5] - The partnership aims to improve oversight, inspection readiness, and collaboration across Neuraxpharm's network of over 100 contract development and manufacturing organizations (CDMOs) [1][2] Company Overview - Neuraxpharm is a leader in the pharmaceutical industry, focusing on disorders affecting the central nervous system (CNS) [2] - Veeva Systems is recognized as a global leader in cloud software for the life sciences sector, serving over 1,000 customers, including major biopharmaceutical companies and emerging biotechs [5] Product Features - Veeva Vault QualityDocs facilitates efficient GxP content management and information sharing across Neuraxpharm's sites [2] - Veeva Vault Training allows Neuraxpharm to deploy training and curricula to ensure GxP compliance [2] - The integration of these applications is expected to streamline content and training, enabling Neuraxpharm to scale its operations as it expands its product portfolio [5]